title: BML-111, a lipoxin receptor agonist, protects haemorrhagic shock-induced acute lung injury in rats.
abstract: OBJECTIVE
  The main pathogenesis of acute lung injury induced by haemorrhagic shock is inflammation. BML-111, a lipoxinA(4)-receptor agonist, promotes acute inflammatory resolution. We sought to elucidate whether BML-111 protects haemorrhagic shock-induced acute lung injury in rats.
  
  
  METHODS
  Thirty two adult male rats were randomized to sham group (sham), haemorrhagic shock/resuscitation (HS), HS plus BML-111 (BML-111), and HS plus BML-111 and BOC-2 (BOC-2). Haemorrhagic shock was induced by blood drawing, and then resuscitation was obtained by infusion of shed blood and two-fold volume saline.
  
  
  RESULTS
  Histological findings, as well as assays of neutrophilic infiltration (myeloperoxidase activity, ICAM-1 expression), inflammatory cytokines and pro-inflammatory factor (IκB-α and NF-κB p65) confirmed that haemorrhagic shock induced acute lung injury. BML-111 significantly mitigated acute lung injury induced by haemorrhagic shock. However, BOC-2, an antagonist of the lipoxinA(4)-receptor, partially reversed the protective effect of BML-111 on the haemorrhagic shock-induced the acute lung injury.
  
  
  CONCLUSIONS
  BML-111 protects haemorrhagic shock-induced acute lung injury in rats.
authors.affiliation: Department of Anesthesiology and Critical Care, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Gong
authors.forename: Si
authors.initials: S
authors.lastname: Guo
authors.forename: Hong-Bin
authors.initials: HB
authors.lastname: Li
authors.forename: Shi-Ying
authors.initials: SY
authors.lastname: Yuan
authors.forename: You
authors.initials: Y
authors.lastname: Shang
authors.forename: Shang-Long
authors.initials: SL
authors.lastname: Yao
mesh_terms: D055371:Acute Lung Injury / Q000517:prevention & control*; D000818:Animals; D015153:Blotting, Western; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D024202:Electrophoretic Mobility Shift Assay; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D044067:Receptors, Lipoxin; D012151:Resuscitation; D012771:Shock, Hemorrhagic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: C530770:5(S),6(R)-7-trihydroxyheptanoic acid, methyl ester; D015815:Cell Adhesion Molecules; D006538:Heptanoic Acids; D016328:NF-kappa B; D009842:Oligopeptides; D044067:Receptors, Lipoxin; C033373:butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine